AVRO-RD-01-201, Phase2 Gene Therapy Study

Please see the below release from Avrobio.

 

Interested in participating? AVRO-RD-01-201 is a Phase2, open-label multinational clinical trial designed to evaluate the safety and efficacy of AVR-RD-01, an ex vivo, lentiviral vector-mediated gene therapy in individuals with Fabry disease.

Eligibility criteria:

• Are between the ages of 16 and 50
• Confirmed diagnosis of classic Fabry disease
• Have had no enzyme replacement therapy (ERT) in the last 10 years and chaperone therapy naïve.

The AVRO trial is being conducted around the world and in sites in Canada. If you are interested in participating please send us a message at the Canadian Fabry Association or reach out directly to Dr. Aneal Khan at the Children’s Alberta Hospital at : aneal.khan@ahs.ca or Shelly Jelinski at Shelly.Jelinski@albertahealthservices.ca for more information. Please call Shelly at 403-955-7874

Study information website: https://avrobiofabrytrial.com/